Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. Despite the expansion of ophthalmic drugs, the effective treatment for AMD remains a major obstacle. Several studies have demonstrated that targeting multiple miRNAs provides effective therapeutic protection against AMD. However, the toxicity of synthetic lipid nanoparticles was apparent preventing their use as therapeutic carriers in human applications. Thus, more natural delivery options, such as cell-derived vesicles (CDVs) need to be investigated. Previously, we have reported the immunomodulatory capacity of CDVs in several inflammatory or degenerative diseases. Here, we assessed the safety and therapeutic potential of CDVs by examining retinal function in an AMD mouse model. Our results demonstrate the potential of CDVs as a novel therapeutic for slowing the progression of AMD. Additionally, we present our strategy to augment therapeutic effects by delivering miRNAs that are known for retinal protection on CDVs.
| Original language | English |
|---|---|
| Pages (from-to) | S119-S120 |
| Journal | Cytotherapy |
| Volume | 25 |
| Issue number | 6, Supplement |
| DOIs | |
| Publication status | Published - May 2023 |
| Event | The 29th Annual ISCT Meeting 2023: International Society for Cell & Gene Therapy - Palais des Congres de Paris, Paris, France Duration: 31 May 2023 → 3 Jun 2023 Conference number: 29 https://www-sciencedirect-com.virtual.anu.edu.au/journal/cytotherapy/vol/25/issue/6/suppl/S |